When the FDA comes down on drug manufacturers, it can be for a range of wrongdoings, including poor testing policies and unsanitary conditions. But shredding key documents and leading investigators to incorrect rooms during an inspection? That's a bold move, and Indian drugmaker Windlas could pay the price.
Windlas Healthcare Private Limited Receives FDA Warning Letter
Sunstar Guangzhou Ltd on FDA Import Alert List
Tecfidera (dimethyl fumarate) : Biogen International v. Windlas Healthcare